Pradelli, L. et al. 2018. Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model. Farmeconomia. Health economics and therapeutic pathways. 19, 1 (Jan. 2018). DOI:https://doi.org/10.7175/fe.v19i1.1328.